持续气道正压通气处方与肥胖合并重度阻塞性睡眠呼吸暂停患者死亡率的关联:睡眠心脏健康研究
该多中心、人群队列研究基于睡眠心脏健康研究(SHHS)数据,比较肥胖合并重度阻塞性睡眠呼吸暂停(OSA)患者中接受(n=81)与未接受(n=311)持续气道正压通气(PAP)处方者的全因死亡率,中位随访11.1年。结果显示处方PAP与全因死亡率降低相关(多变量Cox HR 0.38,95%CI 0.18-0.81;倾向匹配后HR 0.58,95%CI 0.35-0.96),生存曲线差异在PAP启动后6至7年出现。
要点
- 在肥胖合并重度OSA患者中,PAP处方与全因死亡率降低相关(多变量Cox HR 0.38,95%CI 0.18-0.81)。
- 倾向匹配后PAP处方与全因死亡率降低的关联仍存在(HR 0.58,95%CI 0.35-0.96)。
- 生存曲线显示死亡率差异在PAP启动后6至7年出现。
核心结论
- PAP处方与全因死亡率降低相关,且该关联在PAP启动数年后才显现。
- 若这些发现被重复验证,可能具有重要临床意义。
研究设计与样本
- 多中心、人群队列研究,基于睡眠心脏健康研究(SHHS)长期观察性队列数据,纳入1995年至1998年参与者,平均随访11.1年。
- 分析于2018年9月进行;将肥胖合并重度OSA患者按年龄、性别和呼吸暂停低通气指数匹配后,比较接受PAP处方者(n=81)与未接受PAP处方者(n=311)。
- 暴露因素为自我报告的PAP使用;主要结局为全因死亡率。
主要发现
- 392名参与者中316名(80.6%)为男性,平均(标准差)年龄63.1(11.0)岁。
- 共发生96例死亡,其中PAP处方组12例,非PAP处方组84例;粗发病率分别为每1000人年12.8例 vs 24.7例。
- 多变量Cox分析中,PAP处方与全因死亡率的HR为0.38(95%CI 0.18-0.81)。
- 倾向匹配后,PAP处方与全因死亡率的HR为0.58(95%CI 0.35-0.96)。
- 生存曲线显示,死亡率差异在PAP治疗启动后6至7年出现。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The association of positive airway pressure (PAP) with reduced mortality in patients with obstructive sleep apnea (OSA) remains uncertain. OBJECTIVE: To investigate the association between PAP prescription and mortality. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, population-based cohort study evaluated data from the Sleep Heart Health Study (SHHS), a long-term observational cohort study that included participants between 1995 and 1998, with a mean follow-up of 11.1 years. Analyses were performed in September 2018. Within the SHHS, we compared patients with obesity and severe OSA with (n = 81) and without (n = 311) prescription of PAP therapy, after matching patients from each group by age, sex, and apnea-hypopnea index. EXPOSURES: Self-reported use of PAP. MAIN OUTCOMES AND MEASURES: All-cause mortality. RESULTS: Of 392 study participants, 316 (80.6%) were men, and mean (SD) age was 63.1 (11.0) years. Ninety-six deaths occurred; 12 among the prescribed-PAP group and 84 among the nonprescribed-PAP group, yielding crude incidence rates of 12.8 vs 24.7 deaths per 1000 person-years. In Cox multivariate analysis, the hazard ratio (HR) of all-cause mortality for prescribed PAP therapy was 0.38 (95% CI, 0.18-0.81). After propensity matching, the HR of all-cause mortality for prescribed PAP therapy was 0.58 (95% CI, 0.35-0.96). According to survival curves, the difference in mortality appears 6 to 7 years after initiation of PAP therapy. CONCLUSIONS AND RELEVANCE: Positive airway pressure prescription is associated with reduced all-cause mortality, and this association appears several years after PAP initiation. If replicated, these findings may have strong clinical implications.
引用
- Lisan Q, Van Sloten T, Marques Vidal P, et al. Association of Positive Airway Pressure Prescription With Mortality in Patients With Obesity and Severe Obstructive Sleep Apnea: The Sleep Heart Health Study. JAMA Otolaryngol Head Neck Surg. 2019. PMID: 30973594. doi:10.1001/jamaoto.2019.0281
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。